Teva Pharma (TEVA) Q4 2025 earnings review
A $500 Million Bonus Masks a Declining 2026 Outlook
Teva closed 2025 with a massive beat—Revenue up 11% and Non-GAAP EPS hitting $0.96 (vs $0.71 prior year). However, the headline numbers are heavily distorted by a one-time $500M milestone payment for the duvakitug asset. Excluding this windfall, Q4 revenue growth was muted. While the innovative portfolio (Austedo, Ajovy, Uzedy) is accelerating beautifully (+35%), the legacy generics business remains stagnant. Consequently, FY26 guidance points to a 'Reversing' trend, with revenue and earnings guided down year-over-year as the one-time milestone rolls off.
🐂 Bull Case
The 'Pivot to Growth' is working where it counts. Innovative brands generated >$1B in Q4 alone. Austedo (+40%), Ajovy (+68% in US), and Uzedy (+28%) are scaling rapidly, fundamentally improving the margin profile.
Net debt dropped to $13.3B from $14.5B a year ago. With net leverage dropping and cash flow strong ($2.4B FY25), the balance sheet risk that plagued Teva for a decade is fading.
🐻 Bear Case
Without the $500M duvakitug payment, Q4 revenue was essentially flat ($4.21B vs $4.23B in 24Q4). FY26 guidance confirms this reality, forecasting a revenue decline to $16.4-16.8B.
International Markets revenue collapsed 20% in Q4, and Europe fell 3%. The divestiture of the Japan business is hurting the top line, and European generics face continued pricing/volume pressure.
⚖️ Verdict: ⚪
Neutral. The innovative execution is excellent, but the base business is shrinking. Investors should look past the Q4 headline beat and focus on the FY26 guidance, which implies a return to revenue contraction.
Key Themes
The $500M Duvakitug Impact
A massive $500M milestone payment from Sanofi for the duvakitug (anti-TL1A) Phase 3 initiation landed in Q4. This single line item accounted for nearly all of the Q4 revenue beat and significantly inflated margins (US Gross Margin hit 69% vs 55.6% prior year). Investors must strip this out to model FY26 correctly.
Austedo & Uzedy Momentum
Accelerating. Austedo US sales surged 40% YoY to $725M. Uzedy, critical for the psych franchise, grew 28% YoY to $55M. These high-margin assets are successfully filling the hole left by declining legacy products like Copaxone and generic erosion.
International Markets Retreat
Reversing. International Markets revenue plummeted 20% to $528M. While the Japan business divestiture was a known strategic move, the remaining segment profit collapsed 50% to just $70M. This segment is no longer a meaningful profit driver for the company.
Generics: The Stagnant Core
Stable/Weak. US Generics were flat ($673M vs $674M). Europe Generics rose 5% reported but fell 4% in local currency. The 'Generics Powerhouse' narrative is holding steady in the US but struggling with price/volume in Europe. It provides cash flow but zero growth.
Europe Segment Weakness
Decelerating. Europe revenue fell 3% to $1.31B (down 10% in local currency). Segment profit dropped 30% to $308M due to lower gross profit and higher expenses. The region is facing significant headwinds from the sale of product rights and lower generic volumes.
Transformation Savings Realized
Accelerating. Teva achieved $70M in net savings in 2025 and expects to realize two-thirds of its $700M target by 2026. This operational discipline is crucial as the company navigates the revenue valley in FY26.
Other KPIs
Strong beat vs FY24 ($2.07B). Driven by operating cash flow of $1.65B and securitized trade receivables. This fueled a $1.2B reduction in Net Debt to $13.3B.
Accelerating. Up from 26.2% in FY24. However, Q4 margin was an unsustainable 32.5% due to the $500M milestone. Excluding that, margins are improving but not at that velocity.
Down from $14.5B in 2024. The company has successfully paid down $1.8B in senior notes at maturity. Leverage ratio continues to improve towards investment grade targets.
Guidance
Reversing. Down ~3-5% vs FY25 ($17.3B). This decline is almost entirely due to the non-recurrence of the $500M duvakitug milestone and the Japan divestiture overlap. Base business growth is implied to be flat to slightly up.
Stable/Decelerating. The range midpoint ($5.15B) is below FY25 actuals ($5.3B). The milestone loss creates a $400M+ headwind that underlying growth is struggling to fully offset in the immediate term.
Reversing. Down significantly from $2.93 in FY25. The high-margin nature of the lost milestone payment hits EPS hard.
Stable. Midpoint ($2.2B) is slightly below FY25 ($2.4B), reflecting the loss of the milestone cash contribution, partially offset by transformation savings.
Key Questions
Europe Profitability Erosion
Europe segment profit fell 30% in Q4 with margins compressing significantly. Is this structural due to pricing pressure, or a temporary mix issue?
Generic Stability
US Generics were flat year-over-year. With the Biosimilar portfolio expanding, when do we expect the US Generics segment to return to consistent growth?
Austedo Saturation
Austedo growth remains impressive (+40%), but with IRA pricing implementation looming in 2027, does the FY26 guidance assume any pre-emptive pricing pressure or inventory adjustments?